Childhood Liver Cancer: Hepatoblastoma, HCC & HBC Types

Liver cancer in children is thankfully rare, but when it does occur, it often presents a complex diagnostic and therapeutic challenge. Even as the two most common types are hepatoblastoma (HB) and hepatocellular carcinoma (HCC), a growing understanding reveals a significant number of pediatric liver cancers exhibit features of both. These cases are now classified as hepatoblastoma with carcinoma features (HBC) and recent research is beginning to illuminate how these tumors emerge and respond to treatment.

Understanding the Spectrum of Pediatric Liver Cancers

For decades, HB and HCC were considered distinct entities. Hepatoblastoma, the most frequent type, typically affects children under three years old and is often linked to genetic syndromes. Hepatocellular carcinoma, more common in older children and adolescents, shares similarities with adult liver cancer and can be associated with chronic liver disease. However, clinicians have long observed cases that didn’t neatly fit into either category. These tumors, now recognized as HBC, present a mixed picture, making diagnosis and treatment planning more challenging.

A study highlighted by Baylor College of Medicine reveals recent insights into the development of these HBC tumors. Researchers are working to understand the specific genetic and molecular changes that drive their formation and progression. This is crucial because HBC tumors often respond differently to standard therapies compared to either pure HB or HCC.

The Origins of Hepatocellular Carcinoma and Metabolic Zonation

Beyond the specifics of HBC, understanding the broader origins of liver cancer, including HCC, is vital. Research published in Science | AAAS suggests that the origin of hepatocellular carcinoma is closely tied to metabolic zonation within the liver. The liver isn’t a homogenous organ; different zones have distinct metabolic functions. This zonation influences where cancer cells are most likely to arise and how they behave. This research highlights the importance of considering the liver’s complex internal organization when studying and treating liver cancer.

Treatment Advances: Atezolizumab Combinations

Treatment options for pediatric liver cancer are continually evolving. Recent findings suggest that combining atezolizumab with other therapies may offer improved outcomes for certain types of liver cancer. Oncology News Central reports that an atezolizumab combination may be superior to Transarterial Chemoembolization (TACE), a common treatment for HCC, in specific cases. Atezolizumab is an immunotherapy drug that helps the body’s immune system recognize and attack cancer cells. However, it’s important to note that this research focuses on adult HCC and the applicability to pediatric cases, including HBC, requires further investigation.

What Does This Mean for Children with HBC?

The identification of HBC as a distinct category is a significant step forward. It acknowledges the unique characteristics of these tumors and the need for tailored treatment approaches. The Baylor College of Medicine study, and others like it, are working to pinpoint the specific molecular drivers of HBC, which could lead to the development of targeted therapies. Currently, treatment typically involves a combination of surgery, chemotherapy, and sometimes liver transplantation. However, the optimal treatment strategy for HBC remains an area of active research.

It’s crucial to understand that these are complex cancers, and treatment decisions are highly individualized. Factors such as the child’s age, overall health, the extent of the tumor, and the specific genetic features of the cancer all play a role. Parents and caregivers should work closely with a multidisciplinary team of pediatric oncologists, surgeons, and other specialists to develop the most appropriate treatment plan.

The Importance of Continued Research and Surveillance

The rarity of pediatric liver cancer presents a challenge to research efforts. Collaboration between institutions and international registries is essential to collect enough data to conduct meaningful studies. Researchers are also exploring the potential of genomic sequencing to identify new therapeutic targets and predict treatment response.

Ongoing surveillance is also critical. Early detection can significantly improve outcomes. While there is no routine screening for liver cancer in children, healthcare providers should be vigilant for signs and symptoms, such as abdominal swelling, pain, jaundice (yellowing of the skin and eyes), and unexplained weight loss.

What Comes Next: Refining Treatment Strategies

The field of pediatric liver cancer is rapidly evolving. Several clinical trials are underway to evaluate new therapies and treatment combinations. Researchers are also investigating the role of immunotherapy in treating HBC and other types of pediatric liver cancer. The goal is to develop more effective and less toxic treatments that can improve the long-term survival and quality of life for children affected by these rare and challenging cancers. Future research will likely focus on personalized medicine approaches, tailoring treatment to the specific genetic and molecular profile of each child’s tumor.